Semaglutide · 3 min read
Wegovy flat at $349, a $199 two-fill starter offer, the $149 pill intro, Ozempic's parallel pricing, and compounded programs from $133 — every real self-pay number, with its conditions.
Wegovy flat at $349, a $199 two-fill starter offer, the $149 pill intro, Ozempic's parallel pricing, and compounded programs from $133 — every real self-pay number, with its conditions.
Semaglutide's cash market simplified dramatically after the manufacturer price cuts of late 2025, and the 2026 answer fits in one sentence: FDA-approved semaglutide costs $349 a month self-pay at essentially every dose, with introductory offers as low as $149–$199, while verified compounded programs run $133 to $299. The conditions attached to each number are where the money is.
Through NovoCare Pharmacy — or via digital savings card at more than 70,000 retail pharmacies — Wegovy costs a flat $349 a month at every standard injectable dose (0.25 through 2.4 mg), with the 7.2 mg HD tier at $399. New self-pay patients get the first two starter-dose fills at $199 each under a limited-time offer, and the oral Wegovy tablet launched at $149 introductory on its lower doses. Ozempic carries parallel $349 self-pay pricing for cash-paying diabetes patients. Fine print that matters: offers exclude Medicare, Medicaid, TRICARE, and other government-program beneficiaries; introductory rates expire on their own schedules; and the flat structure means your maintenance dose costs what your starter dose cost — a simplicity no dose-scaled program matches.
Verified compounded semaglutide runs $133 (Oak Longevity) to $299 (Remedy) in our feed, with the value cluster at $145–$178 (NexLife, Yucca, IVIM all-in caveats, Found's prepaid year, Mochi all-in) — the full prose ranking carries every condition. The standing caveats: not FDA-approved, post-shortage legal footing narrowed to contested patient-specific pathways, quality varies by pharmacy, and dose-capped outliers (Noom's 0.6 mg at $199) are cheaper because they are a different product. The brand-versus-compounded gap at standing rates is now $171–$216 a month — a real number, and much smaller than the four-figure gap that built this market.
Before paying any cash rate: 43% of large employers now cover weight-loss medication, so an assumption of "not covered" deserves an annual re-check; the SELECT cardiovascular indication opens coverage doors for patients with established heart disease that obesity-exclusion language doesn't close; HSA/FSA dollars apply to all of the above, effectively discounting by your tax rate; and TrumpRx lists Wegovy alongside Zepbound in the ~$350 band, a second door to the same pricing. The insurance guide walks the coverage side in full.
A flat $349/month self-pay at every standard dose via NovoCare or participating retail pharmacies ($399 for the 7.2 mg HD dose), with a limited $199 offer on the first two starter fills and a $149 introductory rate on the new oral tablet.
Verified compounded programs start at $133/month (Oak Longevity, with state and plan conditions). Among FDA-approved products, the oral Wegovy $149 introductory rate is the floor, reverting toward $349.
They are priced in parallel at $349 self-pay in 2026. Ozempic is the diabetes-labeled product; using it for weight loss is off-label prescribing territory that belongs with your clinician.